A single clotting time rarely identifies a bleeding or thrombotic disorder. A prolonged result can come from a missing factor, a circulating inhibitor, a drug, or an unsuitable specimen, and the laboratory distinguishes those causes with the specimen check, the screening pattern, the mixing response, and a targeted assay. A normal prothrombin time (PT) and activated partial thromboplastin time (APTT) do not exclude platelet function disorders, von Willebrand disease (VWD), or factor XIII deficiency. In consumptive disease, the serial trend is more informative than a single value, and reagent sensitivity determines how a lupus anticoagulant or an anticoagulant drug appears in a clotting time.
Disease patterns
Acquired factor deficiency and dysfunction
Scroll sideways to see all columns
| Setting | Main hemostatic disturbance | Typical laboratory pattern |
|---|---|---|
| Major trauma | Dilution, consumption, platelet dysfunction, hypothermia, acidosis, endothelial activation, and fibrinolytic disturbance | Falling platelets and fibrinogen; prolonged PT/APTT in advanced disease; viscoelastic tracing may show delayed clot formation, weak clot, or excess lysis |
| Liver disease | Reduced synthesis of procoagulants and natural anticoagulants, dysfibrinogenemia, thrombocytopenia, and platelet dysfunction | PT often prolongs early through factor VII reduction; factor V may fall; fibrinogen can rise as an acute-phase reactant and decline in advanced failure |
| Vitamin K deficiency or vitamin K antagonist exposure | Impaired gamma-carboxylation of factors II, VII, IX, and X and proteins C, S, and Z | PT prolongs first through factor VII; APTT may prolong as deficiency deepens; mixing usually shows a factor-deficiency pattern |
| Advanced kidney disease | Uremic platelet adhesion, secretion, and aggregation dysfunction | Mucocutaneous bleeding with a normal PT and APTT; platelet-function results vary with anemia, count, and method |
| Nephrotic syndrome | Urinary loss of low-molecular-weight procoagulants and regulatory proteins | Antithrombin falls most consistently, with variable protein C and protein S change; when regulatory-protein loss predominates the net tendency is venous thrombosis, and acute illness makes inherited-deficiency testing unreliable |
| Massive transfusion or volume replacement | Dilution plus the underlying consumption or bleeding process | Falling platelets and fibrinogen, followed by broader clotting-time changes |
In liver disease, hemostasis is rebalanced. Procoagulants and anticoagulants can fall together, and factor VIII and VWF may be preserved or increased. PT and INR were calibrated for vitamin K antagonist monitoring and reflect only part of the bleeding-thrombosis balance in cirrhosis. Factor V is not vitamin K dependent, so a low factor V with a low factor VII favors reduced hepatic protein production. A low factor VII with a normal factor V favors isolated vitamin K deficiency. Moderate to severe disease can also release a hypersialylated fibrinogen that polymerizes slowly, giving a dysfibrinogenemia pattern with a prolonged thrombin time and a markedly prolonged reptilase time. Splenic sequestration from portal hypertension adds thrombocytopenia. Chronic compensated disseminated intravascular coagulation (DIC) can be superimposed. To distinguish it from cirrhosis alone, look for a credible trigger and a serial consumptive trend. Liver enzymes do not make the distinction.
Vitamin K supports gamma-carboxylation of factors II, VII, IX, and X and proteins C, S, and Z. Body stores are small, so deficiency follows malabsorption, biliary obstruction, prolonged parenteral nutrition, or antibiotic disruption of the intestinal flora that supplies part of the daily requirement. Vitamin K deficiency bleeding of the newborn reflects low stores at birth, a sterile gut, and little vitamin K in breast milk. Because factor VII has a short half-life, the PT is the first screening test to prolong, and single-factor assays show factor VII falling first, then IX and X, then II. Warfarin produces the same biochemical defect and releases noncarboxylated, nonfunctional proteins called PIVKA. In either state a prolonged PT that corrects on mixing supports a factor-deficiency pattern. Both conditions transiently lower protein C and protein S, which makes congenital thrombophilia testing uninterpretable during the deficiency.
Hereditary factor deficiencies
Hemophilia A is factor VIII deficiency and hemophilia B is factor IX deficiency. Both are X-linked recessive and clinically indistinguishable, producing deep muscle, joint, and soft-tissue bleeding. Hemophilia A accounts for roughly 85% of hemophilia and hemophilia B roughly 14%. Both usually produce an isolated prolonged APTT, an immediate mixing correction, and reduced activity in the corresponding factor assay. Factor VIII circulates bound to VWF, so evaluate a low factor VIII result for VWD as well, especially type 2N or type 3. Women and girls with an F8 or F9 variant can have low factor activity and clinically important bleeding, and those below 40 IU/dL are classified by the same severity bands. Molecular testing is definitive when the family variant is known. The measured activity defines severity:1
Scroll sideways to see all columns
| Factor VIII or IX activity | Hemophilia severity | Expected pattern |
|---|---|---|
| Below 1 IU/dL | Severe | Spontaneous joint, muscle, and soft-tissue bleeding |
| 1–5 IU/dL | Moderate | Bleeding after minor injury; occasional spontaneous bleeding |
| Above 5 to below 40 IU/dL | Mild | Bleeding with surgery, dental work, or major injury |
Factor XI deficiency, also called hemophilia C or Rosenthal syndrome, is autosomal and is reported disproportionately in Ashkenazi Jewish populations. Its bleeding tendency is mild to moderate and correlates poorly with the measured factor XI activity. Contact-factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen, can cause a striking APTT prolongation without a bleeding tendency.
Scroll sideways to see all columns
| Deficiency | PT | APTT | Thrombin time | Main interpretation |
|---|---|---|---|---|
| Factor VII | Prolonged | Normal | Normal | Isolated extrinsic-pathway defect |
| Factor VIII, IX, or XI | Normal | Prolonged | Normal | Intrinsic-pathway deficiency with bleeding potential |
| Factor XII, prekallikrein, or HMWK | Normal | Prolonged | Normal | Contact activation defect without a bleeding phenotype |
| Factor II, V, or X | Prolonged | Prolonged | Normal | Common-pathway deficiency |
| Fibrinogen deficiency or severe dysfunction | Prolonged | Prolonged | Prolonged | Low or poorly functioning fibrinogen |
| Factor XIII | Normal | Normal | Normal | Delayed bleeding, poor wound healing, or umbilical bleeding requires a specific factor XIII activity assay |
A quantitative factor XIII activity assay is the preferred screen when the phenotype fits. Clot solubility tests detect only profound deficiency and can miss clinically important partial deficiency. One-stage factor assays can be influenced by APTT reagent, lupus anticoagulant, heparin, direct oral anticoagulants, and some factor replacement products. A chromogenic factor VIII or IX assay provides an alternate measurement principle when the one-stage result conflicts with the clinical or treatment setting.2
Inhibitors
A specific factor inhibitor and a lupus anticoagulant can both prevent correction in a mixing study. Their clinical and assay patterns differ:
- Specific factor VIII inhibitor. Acquired hemophilia A typically causes new bleeding, an isolated prolonged APTT, low factor VIII activity, and a time-dependent inhibitor pattern. Incubation can reveal inhibition after an immediate mix appeared to correct. These autoantibodies follow type II kinetics, meaning rapid early inactivation that plateaus with measurable residual factor VIII, so the titer is only semiquantitative. A Nijmegen-Bethesda assay quantifies the inhibitor.
- Alloantibody in congenital hemophilia. Exposure to therapeutic factor can produce a neutralizing antibody that follows type I kinetics: complete, dose-proportional neutralization and a reliable titer. A low-responding inhibitor stays below 5 Nijmegen-Bethesda units per milliliter (BU/mL) and does not rise on re-exposure. A high-responding inhibitor reaches 5 BU/mL or more at any time and rises with further exposure. Report the inhibitor titer alongside factor activity and the treatment context.
- Lupus anticoagulant. An antiphospholipid antibody interferes with phospholipid-dependent clotting reactions. It produces an in-vitro inhibitor pattern and is clinically associated mainly with thrombosis or pregnancy morbidity. Rare lupus-hypoprothrombinemia can add bleeding through low prothrombin.
- Acquired VWF disorder. Accelerated clearance, adsorption to abnormal cells, shear-related loss of high-molecular-weight multimers, or an antibody can create a VWD-like panel with new-onset bleeding. A childhood bleeding history is usually absent, which distinguishes it from congenital VWD. Interpret it with the associated cardiac, lymphoid, myeloid, endocrine, or autoimmune disorder.
Thrombophilia and heparin-induced thrombocytopenia
Inherited thrombophilia is suspected with thrombosis at a young age, at an unusual site such as the mesenteric, renal, or axillary vein, with recurrent events, or with a strong family history.
Scroll sideways to see all columns
| Defect | Mechanism |
|---|---|
| Antithrombin deficiency | Loss of the principal inhibitor of thrombin, Xa, IXa, and XIa |
| Protein C deficiency | Loss of activated protein C mediated inactivation of Va and VIIIa |
| Free protein S deficiency | Loss of the activated protein C cofactor |
| Factor V Leiden | R506Q substitution removes an activated protein C cleavage site on factor V; the most common inherited thrombophilia |
| Prothrombin G20210A | 3′ untranslated-region variant with a modestly raised prothrombin concentration; the second most common |
Most heterozygous carriers never develop thrombosis. Risk increases when one defect combines with another or with an acquired risk factor, so interpret a positive result with the whole clinical picture. Acquired risks include antiphospholipid antibodies, cancer, pregnancy and the postpartum state, estrogen exposure, immobility, surgery, myeloproliferative neoplasms, and paroxysmal nocturnal hemoglobinuria. Chronic inflammation raises fibrinogen and factor VIII and lowers free protein S through increased C4b-binding protein.
A broad inherited panel is rarely useful during an acute event or active anticoagulation. The 2023 American Society of Hematology guideline favors testing only in selected situations where the result would change a management decision. It advises against routine testing for many common venous thromboembolism presentations.3
Common MTHFR polymorphisms are excluded from inherited thrombophilia panels because they lack diagnostic validity. Hyperhomocysteinemia is associated with thrombosis, but causation is not established, and lowering homocysteine with folate has not been shown to prevent venous thrombosis.
Heparin-induced thrombocytopenia (HIT). IgG antibodies against platelet factor 4-heparin complexes can activate platelets through Fc receptors and produce thrombocytopenia with a strong thrombotic risk. The platelet fall commonly begins 5 to 10 days after a new exposure and may occur sooner after recent exposure. Laboratory testing follows clinical pretest probability. With an intermediate or high 4Ts score, which weighs thrombocytopenia depth, timing, thrombosis, and competing causes, test first with a PF4-heparin immunoassay. A positive immunoassay detects binding antibody. Functional testing shows whether that antibody activates donor platelets in a heparin-dependent pattern. With a low 4Ts score, laboratory testing is generally not indicated because false-positive antibody results can lead to a harmful misdiagnosis.4
Disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC) is systemic coagulation activation caused by an underlying disorder. Thrombin generation, fibrin deposition, platelet and factor consumption, and secondary fibrinolysis occur together. Triggers act through tissue factor release in trauma, burns, and adenocarcinoma; endotoxin and cytokine activation in sepsis; immune complexes in acute hemolytic transfusion reaction and in HIT with thrombosis; particulate material in amniotic fluid embolism and placental abruption; proteolytic enzyme release in acute promyelocytic and acute monocytic leukemia and in pancreatitis; and direct toxins such as snake envenomation. Because microthrombi consume platelets and factors faster than marrow and liver replace them, bleeding is often the presenting picture. Schistocytes appear in roughly half of cases as fibrin strands shear erythrocytes in small vessels.
As DIC evolves, platelets fall, PT prolongs, D-dimer rises, and fibrinogen may fall. Early fibrinogen can remain within the interval or rise through the acute-phase response, so the serial trend is more informative than one value. Chronic compensated DIC, as in malignancy or liver disease, can show near-normal or even raised factor levels because production partly keeps pace with consumption, and a raised D-dimer may be the only abnormal result. Apply a DIC score only when a compatible trigger is present.
The 2025 ISTH SSC update assigns points using each laboratory's D-dimer upper limit of normal (ULN):5
Scroll sideways to see all columns
| Component | Finding | Points |
|---|---|---|
| Platelet count | 100 × 10³/µL or higher | 0 |
| 50 to below 100 × 10³/µL | 1 | |
| Below 50 × 10³/µL | 2 | |
| D-dimer | 3 × ULN or lower | 0 |
| Above 3 to 7 × ULN | 2 | |
| Above 7 × ULN | 3 | |
| PT prolongation above control | Below 3 seconds | 0 |
| 3 to below 6 seconds | 1 | |
| 6 seconds or more | 2 | |
| Fibrinogen | 100 mg/dL or higher | 0 |
| Below 100 mg/dL | 1 |
A total of 5 or more is compatible with overt DIC in the proper setting. A lower score does not exclude early disease and calls for serial reassessment. This is one scoring framework with no universal threshold, and baseline thrombocytopenia, liver failure, and anticoagulant therapy each distort a component. Severe liver disease is the closest mimic. It lowers factor production, and DIC consumes factors, so a new consumptive trend and a credible trigger are more informative than any single factor result. Dilutional coagulopathy after massive component transfusion and the obstetric mimics of preeclampsia, HELLP, and acute fatty liver of pregnancy also belong in the differential. Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and other thrombotic microangiopathies usually leave PT, APTT, and thrombin time normal, which distinguishes them from DIC on the coagulation panel.
Coagulation specimens and instruments
Citrated plasma
Plasma clotting assays use blood collected into buffered 3.2% sodium citrate, 0.105 to 0.109 mol/L, at a 9:1 blood-to-anticoagulant ratio. Fill the tube to its validated volume, and mix it promptly and gently. Clots, wrong anticoagulant, substantial underfill, and collection contamination can make the result unusable. Current collection, transport, processing, storage, and rejection guidance is in CLSI H21, 6th edition.6
High hematocrit adjustment. At a hematocrit above 55%, plasma volume is reduced and a standard tube contains excess citrate for that plasma. Excess citrate binds part of the calcium added by the assay and falsely prolongs clotting times. One form of the adjustment for a tube's intended total volume is:
Citrate volume (mL) = [(100 − hematocrit %) ÷ (595 − hematocrit %)] × intended total tube volume (mL)
For an intended 4.5-mL collection at hematocrit 62%:
[(100 − 62) ÷ (595 − 62)] × 4.5 = (38 ÷ 533) × 4.5 = 0.32 mL citrate
Prepare and label the modified tube under a validated laboratory procedure, then fill the remaining volume with blood to the intended total.
Clot-based testing uses platelet-poor plasma with a residual platelet count below 10 × 10³/µL, prepared under the laboratory's validated centrifugation procedure. A single spin near 1,500 × g for 15 minutes in a swinging-bucket rotor is typical. Residual platelets supply phospholipid and release platelet factor 4, which neutralizes heparin, so they can shorten heparin-sensitive results and mask a lupus anticoagulant. Double-centrifuge plasma for lupus anticoagulant testing or for freezing to the same residual platelet limit, and transfer the plasma without disturbing the buffy coat or the pellet.6 Follow assay-specific stability and frozen storage limits. Judge a hemolyzed specimen by its likely in-vivo or in-vitro origin and the assay's validated interference policy, and recollect when the result would be unreliable. Hemolysis, icterus, and lipemia interfere with optical detection. Mechanical clot detection or an analyzer's validated interference correction provides an alternative.
End-point detection
- Mechanical detection senses the physical formation of fibrin by movement of a ball, probe, or electromechanical system and is less vulnerable to specimen color.
- Photo-optical detection follows the increase in turbidity as fibrin forms.
- Chromogenic detection measures color released when an enzyme cleaves a laboratory-made substrate. A direct assay produces more color with more analyte activity. An inhibitory assay, such as heparin anti-Xa, produces less color as analyte activity rises.
- Immunologic detection measures antigen-antibody binding by turbidity, nephelometry, fluorescence, or another validated signal and is common in D-dimer assays.
- Viscoelastic detection follows whole-blood clot initiation, strength, and lysis over time.
Screening tests and mixing studies
PT and INR
PT reagent supplies tissue factor, phospholipid, and calcium to citrated plasma. The result depends on factor VII and the common-pathway factors X, V, II, and fibrinogen. Vitamin K deficiency, warfarin, liver disease, DIC, factor deficiency, and some drugs can prolong it. Factors VIII, IX, XI, XII, and XIII are not measured by the PT.
Each laboratory verifies a reference interval for its reagent and instrument. For vitamin K antagonist monitoring, the international normalized ratio (INR) corrects much of the difference in thromboplastin sensitivity:
INR = (patient PT ÷ mean normal PT)ISI
The international sensitivity index (ISI) is specific to the reagent-instrument system, and an ISI near 1.0 indicates a reagent about as responsive as the WHO international reference thromboplastin. Local verification or calibration supports comparable reporting. INR has a defined role in vitamin K antagonist monitoring. Applying the INR to liver disease or a direct oral anticoagulant is not validated. A lupus anticoagulant prolongs some thromboplastin reagents, which makes the PT and INR unreliable for warfarin monitoring in that patient. A chromogenic factor X assay is the usual substitute. Current one-stage PT and APTT procedure guidance is in CLSI H47, 3rd edition.7
APTT
APTT reagent supplies a contact activator and phospholipid. Recalcification starts clot formation. The assay measures contact factors, XI, IX, VIII, and the common pathway, and is insensitive to factor VII and factor XIII. An isolated prolonged APTT can reflect hemophilia, factor XI or contact-factor deficiency, a specific inhibitor, lupus anticoagulant, unfractionated heparin, a direct thrombin inhibitor, or preanalytic contamination. Fibrin degradation products and paraproteins can also prolong it. Reagent composition changes sensitivity to lupus anticoagulant, heparin, and individual factor reductions, so a normal APTT cannot exclude every mild deficiency or drug effect.
Unfractionated heparin can be monitored with APTT when the laboratory has established a reagent- and instrument-specific therapeutic interval correlated with an accepted heparin measurement. A range near 1.5 to 2.5 times the reference-interval mean is often quoted. Treat it as a starting point for local correlation. It does not transfer between reagent systems. Acute-phase factor VIII elevation can shorten APTT and obscure the heparin effect. Lupus anticoagulant can prolong it independently. A chromogenic anti-Xa assay avoids these particular clot-time effects. It has its own optical and drug interferences.
Mixing studies
A mixing study combines patient plasma 1:1 with pooled normal plasma and repeats the prolonged assay. Normal plasma supplies approximately half-normal activity for a missing factor. An inhibitor acts on the patient's and pooled factor or on the assay phospholipid.
- Review specimen integrity and the medication record. Thrombin time, anti-Xa, or a drug-specific assay can identify heparin or a direct anticoagulant before mixing.
- Test the patient plasma, pooled normal plasma, and immediate 1:1 mix under the same conditions.
- Interpret correction with a locally validated criterion, such as a mixing-test reference interval or an index of circulating anticoagulant. A corrected mix supports deficiency. Persistent prolongation supports inhibitor or drug effect.
- When a time-dependent inhibitor remains possible, incubate patient plasma and the mix at 37 °C for the validated interval, commonly 2 hours, and retest with an incubated control. Factor VIII autoantibodies and a minority of lupus anticoagulants appear only after this step.
- Resolve the pattern with factor activity, lupus anticoagulant, inhibitor titer, or drug testing.
Strong lupus anticoagulants can show partial correction after dilution, and multiple factor deficiencies can show incomplete correction. Mixing classifies a prolonged screen, and the factor, inhibitor, and drug assays that follow identify the cause.
Thrombin time, reptilase time, and heparin neutralization
Thrombin time adds thrombin directly to plasma and measures fibrinogen conversion to fibrin. It is sensitive to low or dysfunctional fibrinogen, heparin, dabigatran and other direct thrombin inhibitors, and high concentrations of fibrin degradation products. A normal thrombin time makes a clinically important dabigatran concentration unlikely when the reagent is sufficiently sensitive.
Reptilase time uses a thrombin-like snake venom enzyme that cleaves fibrinopeptide A and is insensitive to heparin. Parallel prolongation of thrombin and reptilase times supports a fibrinogen quantity or function problem. A prolonged thrombin time with a normal reptilase time supports heparin or a direct thrombin inhibitor. A validated heparinase or polybrene neutralization procedure can confirm heparin interference when correction follows treatment.
Fibrinogen and fibrin turnover
Clauss fibrinogen
The Clauss method dilutes plasma, commonly 1:10 so that heparin and fibrin degradation products interfere less, adds a high thrombin concentration, and converts clotting time to functional fibrinogen against a calibration curve. Clot time is inversely related to fibrinogen across the method's linear interval, often about 100 to 500 mg/dL, though each system defines its own. A PT-derived fibrinogen estimate comes from the optical PT curve and may diverge at concentration extremes or in dysfibrinogenemia. Dysfibrinogenemia can read as hypofibrinogenemia by the Clauss method because the abnormal molecule clots slowly, so comparing functional fibrinogen with fibrinogen antigen identifies the qualitative defect.
D-dimer
D-dimer assays use antibodies against products released from cross-linked fibrin. They document that thrombin formed fibrin, factor XIIIa cross-linked it, and plasmin later digested it. Inflammation, pregnancy, surgery, trauma, cancer, and increasing age can all raise the result. Within a validated clinical algorithm, a result below the assay cutoff can exclude acute venous thromboembolism in a patient with low or selected intermediate pretest probability. A result above the cutoff does not confirm thrombosis and cannot localize it.
Manufacturers report either fibrinogen-equivalent units (FEU) or D-dimer units (DDU). FEU values are often roughly twice DDU values. Assay antibodies and calibrators vary, so interpret the exact unit, assay, and cutoff supplied by the laboratory. The updated DIC score likewise uses multiples of the assay's own ULN.
Platelet and VWF testing
Platelet function
A platelet function analyzer draws citrated whole blood through a collagen-and-agonist-coated aperture under high shear and reports closure time. VWF, platelet count, hematocrit, medication exposure, and preanalytic delay all influence the result. It is a screening adjunct with limited sensitivity for mild VWD and platelet defects.
Light-transmission aggregometry stirs platelet-rich plasma and records rising light transmission as platelets aggregate. It remains the reference functional method. Whole-blood impedance aggregometry records increasing electrical resistance as platelets coat electrodes. Lumiaggregometry adds simultaneous ATP release measurement by a luciferin-luciferase reaction, which can detect a dense-granule secretion defect. Cartridge systems built around one drug-specific agonist give a point-of-care option for antiplatelet monitoring: arachidonic acid for aspirin, ADP for P2Y12 inhibitors, and thrombin receptor-activating peptide for GPIIb/IIIa inhibitors.
Scroll sideways to see all columns
| Agonist | Main laboratory connection |
|---|---|
| ADP | P2Y receptor response and secondary-wave amplification; P2Y12 inhibitors suppress it |
| Epinephrine | Secondary-wave response in platelet-rich plasma |
| Collagen | Adhesion-receptor signaling, secretion, and thromboxane amplification |
| Arachidonic acid | Cyclooxygenase-thromboxane pathway and aspirin effect |
| Ristocetin | VWF-dependent agglutination through platelet Ib-IX-V |
| Thrombin receptor-activating peptide | Strong receptor-mediated activation without clotting the test sample |
The Qualitative Platelet Defects lesson explains the diagnostic response patterns for Glanzmann thrombasthenia, Bernard-Soulier syndrome, and storage-pool disease.
VWF panel
Initial VWD testing combines VWF antigen, platelet-dependent VWF activity, and factor VIII activity. GPIb-binding assays such as VWF:GPIbM and VWF:GPIbR are preferred where available because they are more precise and perform better at low concentrations than the older ristocetin cofactor assay. A platelet-dependent activity-to-antigen ratio below 0.7 supports a qualitative type 2 pattern. Multimer analysis or collagen-binding activity evaluates high-molecular-weight forms. VWF-factor VIII binding or targeted genetics resolves suspected type 2N. Targeted genetics is preferred for suspected type 2B in the 2021 guideline.8
VWF rises during inflammation, stress, pregnancy, and estrogen exposure. Test near baseline health when feasible and interpret with the local interval. The Qualitative Platelet Defects lesson covers the VWD disease types and diagnostic thresholds. This section describes what each laboratory measurement contributes.
Factor and inhibitor assays
A one-stage factor assay mixes serial patient-plasma dilutions with plasma lacking the factor of interest and measures PT or APTT. Correction is compared with a reference-plasma calibration curve. PT-based assays measure II, V, VII, and X. APTT-based assays measure VIII, IX, XI, and XII. Dilution linearity can reveal an inhibitor, lupus anticoagulant, or drug effect. Chromogenic factor assays measure enzyme generation through a laboratory-made substrate and provide a useful alternate principle for factor VIII or IX.
Mild hemophilia A can produce discordant factor VIII activity: some variants have a normal one-stage result but reduced chromogenic activity, and the reverse also occurs. The WFH recommends both methods in the initial investigation of suspected hemophilia A, even when one result is normal. A normal APTT or one-stage result therefore does not end a compatible bleeding investigation.1
Emicizumab binds human factors IXa and X and can shorten APTT while falsely increasing APTT-based factor VIII activity. These results cannot measure endogenous factor VIII or exclude its inhibitor. Use validated chromogenic factor VIII activity and inhibitor assays with bovine reagents that avoid this interaction. WFH specifically recommends bovine factor X. Assays containing human factor IXa may still be affected at high emicizumab concentrations. Passing controls without the drug does not exclude interference in the patient specimen.1
The Nijmegen-Bethesda assay quantifies a factor VIII inhibitor. Patient plasma is mixed 1:1 with imidazole-buffered normal pooled plasma and incubated 2 hours at 37 °C beside a control mixture of factor VIII-deficient plasma and the same buffered pool. Residual factor VIII is then measured against that control. One Nijmegen-Bethesda unit is the inhibitor amount that leaves 50% residual factor VIII under these conditions, and the reciprocal of the neutralizing dilution gives the titer. Predilute a high-titer specimen in factor VIII-deficient plasma, and apply the dilution factor. The CDC modification first heats plasma at 56 °C for 30 minutes and centrifuges it, removing infused or endogenous factor VIII while leaving the antibody measurable, so a patient on replacement therapy does not need a washout before testing.9 Non-factor therapies require assay selection matched to the product.
Lupus anticoagulant and thrombophilia assays
Lupus anticoagulant (LA) testing uses two phospholipid-dependent systems with different principles, usually dilute Russell viper venom time (dRVVT) and an LA-sensitive APTT such as a silica clotting time. Each system evaluates screen, mix, and phospholipid-rich confirm results. A normalized confirmatory ratio showing shorter clotting with excess phospholipid supports phospholipid dependence. Resolve factor deficiency, specific inhibitors, heparin, vitamin K antagonists, and direct oral anticoagulants before assigning an LA interpretation. Cutoffs are reagent- and population-specific.10
Anticardiolipin IgG/IgM and anti-β2-glycoprotein I IgG/IgM are solid-phase immunoassays and complete the antiphospholipid laboratory profile. Persistent positivity requires repeat demonstration at least 12 weeks later for antiphospholipid syndrome classification. The report names the assay, units, cutoff, and anticoagulant limitations.
Antithrombin activity is commonly measured by chromogenic inhibition of added Xa or thrombin. Protein C activity uses chromogenic or clot-based measurement after activation, often with the snake venom activator Protac. Protein S testing separates free antigen, total antigen, and clot-based activated-protein-C cofactor activity. Acute thrombosis, liver disease, DIC, pregnancy, estrogen, warfarin, heparin, nephrotic loss, and direct anticoagulants can alter one or more results. Warfarin lowers protein C and protein S together because both are vitamin K dependent, and protein C falls fastest at a half-life near 6 to 8 hours. Confirm a possible congenital deficiency at a stable baseline once acquired influences resolve. Antigen classification or genetics may also be needed.
Dabigatran inhibits the thrombin added in a thrombin-based chromogenic antithrombin assay. The method may attribute that extra inhibition to antithrombin and overestimate activity, potentially masking deficiency. Direct Xa inhibitors can similarly overestimate activity in Xa-based methods. The direction of interference follows the assay's enzyme target. Drug concentration and reagent sensitivity determine its size. Select a validated unaffected method, or coordinate repeat testing at an appropriate time with the clinical service.11
Factor V Leiden can falsely lower protein S activity in susceptible clot-based assays because it reduces the activated-protein-C-dependent clot prolongation used as the activity signal. Low activity with normal free and total antigen can therefore mimic a qualitative protein S defect. Resolve the method interference and acquired influences before assigning a deficiency type. Normal antigen alone does not exclude a true functional defect. Confirm an apparent deficiency with an appropriate repeat or alternative assessment.12,13
The activated protein C resistance assay compares an APTT-based clotting time with and without added activated protein C, using patient plasma diluted in factor V-depleted plasma so that other factor concentrations do not affect the result. Normal plasma lengthens substantially when activated protein C is added. A factor V Leiden specimen resists that prolongation. The cutoff is specific to the reagent and instrument. A value near 1.8 is one commonly published example.
Suppose a normal specimen clots in 28 seconds without activated protein C and extends to 58 seconds with it, giving 58 ÷ 28 = 2.07. A factor V Leiden specimen also clots in 28 seconds without activated protein C and reaches only 36 seconds with it, giving 36 ÷ 28 = 1.29. Against a 1.8 cutoff the first ratio is normal and the second shows activated protein C resistance.
Direct genotyping confirms factor V Leiden and its zygosity, and it is the only reliable method for prothrombin G20210A, whose prothrombin elevation is too small and too variable for an activity assay to detect. Genetic results stay stable during anticoagulation and acute illness, although test selection still depends on whether the result will change care.
HIT functional testing
PF4-heparin immunoassays range from broad, highly sensitive enzyme immunoassays to rapid methods with different specificity. Optical density or signal strength contributes to post-test probability. A functional assay follows, with the washed-platelet serotonin-release assay as the reference method and the heparin-induced platelet activation assay as an alternative. Patient serum is incubated with donor platelets at low and high heparin concentrations. A true HIT antibody activates platelets at the low therapeutic concentration. Saturating heparin disrupts the PF4-heparin complex that the antibody requires and suppresses activation. That heparin-dependent pattern distinguishes a platelet-activating antibody from a nonpathogenic anti-PF4 antibody. Donor reactivity, assay expertise, and specimen timing influence sensitivity. Report the result with the clinical score and the immunoassay strength.
Viscoelastic and thrombin-generation assays
Thromboelastography and rotational thromboelastometry test citrated or fresh whole blood as a clot forms and lyses. Their tracings describe initiation time, clot-building kinetics, maximum strength, and lysis. Platelets and fibrinogen both contribute to clot strength, and method-specific channels can separate their contributions or expose heparin effect. These assays support targeted assessment in trauma, cardiac surgery, liver transplantation, and other validated protocols. These assays are not reliably sensitive to endothelial function or to many VWF or platelet defects.
A thrombin-generation assay records lag time, peak thrombin, time to peak, and total endogenous thrombin potential. It captures more of the reaction than the first-fibrin endpoint of PT or APTT. Standardization and clinical decision limits remain assay- and setting-specific.
Anticoagulant measurement
Heparins and fondaparinux
The chromogenic anti-Xa assay adds a known amount of Xa to patient plasma. Heparin-accelerated antithrombin neutralizes part of it. Residual Xa cleaves a chromogenic substrate. More heparin yields less color. Some reagents add antithrombin. Others depend on the patient's antithrombin. Match the calibrator to the drug: unfractionated heparin, low-molecular-weight heparin, or fondaparinux.
Unfractionated heparin can be monitored by a locally calibrated APTT or heparin anti-Xa assay. Low-molecular-weight heparin and fondaparinux usually require no routine laboratory monitoring. Selected protocols use a drug-calibrated anti-Xa result collected at a defined post-dose time. A direct Xa inhibitor can falsely elevate a heparin anti-Xa result, and hemolysis, icterus, lipemia, or low antithrombin can affect some methods.
Direct oral anticoagulants
Routine PT and APTT give variable, reagent-dependent responses to direct oral anticoagulants and cannot quantify concentration. A normal PT can coexist with a clinically relevant apixaban level, and a normal APTT with a low or moderate dabigatran level. Drug-specific assays provide the reliable measurement when testing is clinically indicated:14
Scroll sideways to see all columns
| Drug class | Useful laboratory test | Key limitation |
|---|---|---|
| Dabigatran, direct thrombin inhibitor | Dilute thrombin time or ecarin-based assay with dabigatran calibrators | Standard thrombin time is highly sensitive and mainly qualitative |
| Apixaban, rivaroxaban, or edoxaban, direct Xa inhibitors | Chromogenic anti-Xa assay with the specific drug calibrator | A heparin calibration cannot be substituted for a quantitative drug result |
Interpret the result with the collection time relative to the last dose, renal function, dose, and assay calibration. Direct oral anticoagulants can distort PT, APTT, mixing, factor activity, protein C or S activity, activated protein C resistance, and lupus anticoagulant assays. Collection after adequate drug clearance, measurement of the drug, or a validated adsorbent procedure can make the results interpretable again.
Intravenous direct thrombin inhibitors
Argatroban and bivalirudin are commonly followed with APTT under a drug- and protocol-specific target. Activated clotting time is used for selected high-dose procedural settings. Both can prolong PT and INR. During overlap with warfarin, argatroban especially raises INR through assay effect. The laboratory and clinical protocol must account for that combined effect before interpreting the vitamin K antagonist contribution. Before you interpret any clotting time as a factor level, consider the reagent, any drug present, and the specimen.
Practice
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046. Back to text
- Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025. Accessed August 31, 2026. Back to text
- Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-7138. doi:10.1182/bloodadvances.2023010177. Back to text
- Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489. Back to text
- Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356-2362. doi:10.1016/j.jtha.2025.03.038. Back to text
- Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays. 6th ed. CLSI standard H21. Clinical and Laboratory Standards Institute; 2024. Accessed August 31, 2026. Back to text
- Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test. 3rd ed. CLSI standard H47. Clinical and Laboratory Standards Institute; 2023. Accessed August 31, 2026. Back to text
- James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. doi:10.1182/bloodadvances.2020003265. Back to text
- Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10(6):1055-1061. doi:10.1111/j.1538-7836.2012.04705.x. Back to text
- Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828-2839. doi:10.1111/jth.15047. Back to text
- ARUP Laboratories. Impacts of common anticoagulants on coagulation testing. ARUP Consult. Updated February 2024. Accessed September 7, 2026. Back to text
- Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Thrombophilia testing: a British Society for Haematology guideline. Br J Haematol. 2022;198(3):443-458. doi:10.1111/bjh.18239. Back to text
- Rollins-Raval MA, Mitsios JV, Marlar RA. Cost-effective use of the protein S algorithm in thrombophilia testing. J Appl Lab Med. 2022;7(3):794-802. doi:10.1093/jalm/jfab175. Back to text
- Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008-1020. doi:10.1055/a-1450-8178. Back to text